IL308014A - Anti-galectin-9 antibodies and their therapeutic uses - Google Patents

Anti-galectin-9 antibodies and their therapeutic uses

Info

Publication number
IL308014A
IL308014A IL308014A IL30801423A IL308014A IL 308014 A IL308014 A IL 308014A IL 308014 A IL308014 A IL 308014A IL 30801423 A IL30801423 A IL 30801423A IL 308014 A IL308014 A IL 308014A
Authority
IL
Israel
Prior art keywords
galectin
antibodies
therapeutic uses
therapeutic
Prior art date
Application number
IL308014A
Other languages
English (en)
Hebrew (he)
Inventor
Aleksandra Filipovic
Eric Elenko
Heather Paden
Christopher Korth
Original Assignee
Puretech Lyt Inc
Aleksandra Filipovic
Eric Elenko
Heather Paden
Christopher Korth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Lyt Inc, Aleksandra Filipovic, Eric Elenko, Heather Paden, Christopher Korth filed Critical Puretech Lyt Inc
Publication of IL308014A publication Critical patent/IL308014A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL308014A 2021-04-30 2022-04-29 Anti-galectin-9 antibodies and their therapeutic uses IL308014A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163182521P 2021-04-30 2021-04-30
US202163193357P 2021-05-26 2021-05-26
US202263313879P 2022-02-25 2022-02-25
PCT/US2022/027127 WO2022232641A1 (en) 2021-04-30 2022-04-29 Anti-galectin-9 antibodies and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
IL308014A true IL308014A (en) 2023-12-01

Family

ID=83847350

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308014A IL308014A (en) 2021-04-30 2022-04-29 Anti-galectin-9 antibodies and their therapeutic uses

Country Status (8)

Country Link
US (1) US20240190970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329807A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024519450A (cg-RX-API-DMAC7.html)
AU (1) AU2022266821A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217822A1 (cg-RX-API-DMAC7.html)
IL (1) IL308014A (cg-RX-API-DMAC7.html)
WO (1) WO2022232641A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309775B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
CN119033928A (zh) * 2019-05-01 2024-11-29 纽约大学 抗半乳糖凝集素-9抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR102537A1 (es) * 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
WO2019084553A1 (en) * 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
CA3134942A1 (en) * 2019-03-25 2020-10-01 New York University Anti-galectin-9 antibodies and uses thereof
CN119033928A (zh) * 2019-05-01 2024-11-29 纽约大学 抗半乳糖凝集素-9抗体及其用途
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CN116782934A (zh) * 2020-10-26 2023-09-19 纯技术Lyt股份有限公司 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途
WO2022109302A1 (en) * 2020-11-20 2022-05-27 New York University Anti-galectin-9 antibodies and therapeutic uses thereof
US20240109968A1 (en) * 2020-11-20 2024-04-04 New York University Anti-galectin-9 antibodies and therapeutic uses thereof

Also Published As

Publication number Publication date
JP2024519450A (ja) 2024-05-14
ZA202309775B (en) 2025-03-26
EP4329807A4 (en) 2025-03-12
EP4329807A1 (en) 2024-03-06
AU2022266821A9 (en) 2023-11-16
AU2022266821A1 (en) 2023-11-09
US20240190970A1 (en) 2024-06-13
WO2022232641A1 (en) 2022-11-03
CA3217822A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
IL308808A (en) Antibodies against CCR8 and their uses
GB202017058D0 (en) Antibodies and uses thereof
IL307267A (en) ANTI-CD122 antibodies and their uses
GB2610467B (en) Anti-CLL1 antibody and application thereof
IL310662A (en) Anti-CD161 antibodies and their uses
IL319931A (en) Anti-CD122 antibodies and their uses
GB202012331D0 (en) Therapeutic antibodies
IL307940A (en) Anti-ADGRE2 antibodies and their uses
IL289656A (en) Anti-tigit antibodies and their application
IL310810A (en) Anti-ACVR2A antibodies and uses thereof
IL304686A (en) Anti-met antibodies and their uses
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
IL292599A (en) tmem219 antibodies and medical uses thereof
IL327202A (en) Anti-CDH17 antibodies and their uses
IL304412A (en) Antibodies against cd112r and uses thereof
EP4490199A4 (en) MODIFIED ANTIBODIES AND THEIR USES
IL307939A (en) Anti-CLEC12A antibodies and uses thereof
IL312584A (en) ANTI-VISTA antibodies and their uses
IL310028A (en) Antibody and its use
EP4437000A4 (en) ANTI-TREM2 ANTIBODY AND ITS USES
IL307233A (en) Anti-SEMA3A antibodies and uses thereof
EP4352106A4 (en) ANTI-UPAR ANTIBODIES AND THEIR USES
IL320972A (en) Anti-TFR1 antibodies and their uses
IL308198A (en) Anti-IL-27 antibodies and uses thereof
GB202303531D0 (en) Antibodies and uses thereof